P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).

Detalles Bibliográficos
Autores principales: Macro, M., Touzeau, C., Mariette, C., Manier, S., Brechignac, S., Vincent, L., Hebraud, B., Decaux, O., Schulmann, S., Lenoir, C., Godmer, P., Farge, A., Peyro Saint Paul, L., Parienti, J.-J., Leleu, X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429165/
http://dx.doi.org/10.1097/01.HS9.0000846584.41392.46
_version_ 1784779352759599104
author Macro, M.
Touzeau, C.
Mariette, C.
Manier, S.
Brechignac, S.
Vincent, L.
Hebraud, B.
Decaux, O.
Schulmann, S.
Lenoir, C.
Godmer, P.
Farge, A.
Peyro Saint Paul, L.
Parienti, J.-J.
Leleu, X.
author_facet Macro, M.
Touzeau, C.
Mariette, C.
Manier, S.
Brechignac, S.
Vincent, L.
Hebraud, B.
Decaux, O.
Schulmann, S.
Lenoir, C.
Godmer, P.
Farge, A.
Peyro Saint Paul, L.
Parienti, J.-J.
Leleu, X.
author_sort Macro, M.
collection PubMed
description
format Online
Article
Text
id pubmed-9429165
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94291652022-08-31 P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM). Macro, M. Touzeau, C. Mariette, C. Manier, S. Brechignac, S. Vincent, L. Hebraud, B. Decaux, O. Schulmann, S. Lenoir, C. Godmer, P. Farge, A. Peyro Saint Paul, L. Parienti, J.-J. Leleu, X. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429165/ http://dx.doi.org/10.1097/01.HS9.0000846584.41392.46 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Macro, M.
Touzeau, C.
Mariette, C.
Manier, S.
Brechignac, S.
Vincent, L.
Hebraud, B.
Decaux, O.
Schulmann, S.
Lenoir, C.
Godmer, P.
Farge, A.
Peyro Saint Paul, L.
Parienti, J.-J.
Leleu, X.
P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
title P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
title_full P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
title_fullStr P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
title_full_unstemmed P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
title_short P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
title_sort p929: ixazomib and daratumumab without dexamethasone (i-dara) in elderly frail relapsing myeloma (rrmm) patients: results of the phase 2 study ifm 2018-02 of the intergroupe francophone du myelome (ifm).
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429165/
http://dx.doi.org/10.1097/01.HS9.0000846584.41392.46
work_keys_str_mv AT macrom p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT touzeauc p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT mariettec p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT maniers p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT brechignacs p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT vincentl p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT hebraudb p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT decauxo p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT schulmanns p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT lenoirc p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT godmerp p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT fargea p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT peyrosaintpaull p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT parientijj p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm
AT leleux p929ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrelapsingmyelomarrmmpatientsresultsofthephase2studyifm201802oftheintergroupefrancophonedumyelomeifm

Ejemplares similares